Patient Dismissal by Primary Care Practices
Patient dismissal, the termination of a relationship with a patient by a health care professional, can affect access to care. Although understudied, the topic is important, especially as insurers begin to shift payment from volume to value. Patient dismissal could be an unintended consequence of this shift as clinicians face (or perceive that they face) pressure to limit their panel to patients for whom they can readily demonstrate value in order to maximize revenue. 1 We examined the prevalence of and reasons for patient dismissal among primary care practices participating in the Comprehensive Primary Care (CPC) initiative and a matched sample of comparison practices. The CPC and responding comparison practices had similar market-, practice-and patient-level characteristics.
2,3
Methods | The New England Institutional Review Board (NEIRB 13-174) exempted the study based on the federal common rule (section 45 CFR 46.101[b] [5]), because the evaluation's purpose is to evaluate a public benefit program. We analyzed the practices' responses to a survey fielded in 2016, the last year of the 4-year CPC initiative. The survey went to practice man- In addition to questions on the practices' characteristics and approaches to delivering care, the survey asked: "In the past 2 years, has your practice ever dismissed a patient from your practice? By dismissing patients, we mean directing patients to leave your practice and seek primary care elsewhere." Respondents who answered "yes" were then asked to identify, from specified response categories, reasons for patient dismissal (Table) . They were also asked to estimate the number of patients dismissed in the past 2 years by choosing any of the following ranges: 1 to 5, 6 to 10, 11 to 20, 21 to 50, or 51 or more. CPC practices were also asked whether participating in the initiative made it more or less likely that they would dismiss patients. We present descriptive statistics from these data on patient dismissal for CPC practices, comparison practices, and overall.
Results | A similar proportion and distribution of CPC and comparison practices reported ever dismissing patients in the past 2 years (394 [89%] and 314 [92%], respectively). Most practices reported dismissing only a few patients in the past 2 years; 86 (about 10%) did not dismiss any patients, and 530 (67%) reported dismissing 1 to 20 patients (Table) . The number of patients dismissed was proportional to practice size (data not shown). CPC and comparison practices dismissed patients for similar reasons. The exception was that comparison practices more frequently reported dismissing patients for violating bill payment policies than did CPC practices (124 [43%] Discussion | Our results provide early evidence on the influence of one alternative payment model on patient dismissal and the reasons for it. According to most CPC practices, the initiative had no effect or made them less likely to dismiss patients. The CPC and comparison groups dismissed patients for similar reasons.
The limitations of our study include the use of survey data, which may be subject to recall or social desirability biases. We used survey data because it was not feasible to review patient medical records or dismissal letters from the 1292 practices.
Our study contributes new insight into an issue that will be increasingly important as insurers move to reimbursing for value rather than volume. Future research could investigate what medical ethicists consider inappropriate reasons for dismissal. 
Heat-Not-Burn Tobacco Cigarettes: Smoke by Any Other Name
The tobacco industry's most recent response to the documented harms of cigarette smoking was to launch new heatnot-burn (HNB) tobacco cigarettes.
1 Philip Morris International (PMI) created IQOS (I-Quit-Ordinary-Smoking): disposable tobacco sticks soaked in propylene glycol, which are inserted in a holder in the HNB cigarette. The tobacco is heated with an electric blade at 350°C. The cigarettes are marketed by PMI as a "revolutionary technology that heats tobacco without burning it, giving you the true taste of tobacco, with no smoke, no ash and less smell."
2 In many countries, laws that protect people from passive smoke only apply to smoked tobacco products. Philip Morris International claims that IQOS releases no smoke because the tobacco does not combust and the tobacco leaves are only heated not burned. However, there can be smoke without fire. The harmful components of tobacco cigarette smoke are products of incomplete combustion (pyrolysis) and the degradation of tobacco cigarettes through heat (thermogenic degradation). Complete combustion occurs at a high temperature (>1300°C), higher than the heat generated by smoking a tobacco cigarette (<800°C). Typical markers of pyrolysis and thermogenic degradation of tobacco cigarettes are acetaldehyde, an irritant carcinogenic volatile organic compound, benzo[a]pyrene, a carcinogenic polycyclic aromatic hydrocarbon, and carbon monoxide. Pilot programs for IQOS began in 2014 in Japan and in 2015 in Switzerland and Italy. An internet survey in Japan published in 2015 suggested that younger individuals (15 to 39 years of age) were more likely to use IQOS, as were former smokers and current smokers.
3 Since 2016, a total of 19 countries have allowed the sale of IQOS cigarettes. In June 2016, data from PMI revealed that IQOS had captured 2.2% of the cigarette market in Japan. IQOS is not yet sold in the United States, but in December 2016, PMI submitted a modified risk tobacco product application to the US Food and Drug Administration. If successful, PMI will be less restricted in its marketing for the IQOS than for conventional tobacco cigarettes. Smokers and nonsmokers need accurate information about toxic compounds released in IQOS smoke. This information should come from sources independent of the tobacco industry, but the only analyses we found were from PMI and PMI competitors. We used a smoking device designed and tested in our facility to capture the mainstream aerosol and developed to meet standards for common cigarettes and e-cigarettes. 4 We followed the International Organization for Standardization standards for puff volume (35 mL) at 2 puffs per minute, based on observation of IQOS smokers, who took a mean of 14 puffs during 5 to 6 minutes. We analyzed volatile organic compounds and nicotine by gas chromatography coupled to a flame ionization detector and polycyclic aromatic hydrocarbons using high-performance liquid chromatography coupled to a fluorescence detector, as previously described. 4 We trapped polycyclic aromatic hydrocarbons from IQOS cigarette smoke in a glass filter (Whatman 37 mm Ø GF/B) mounted in line with an XAD2 cartridge. For each sampling, 10 IQOS cigarettes were smoked. Each sampling support was desorbed in 10 mL of acetonitrile and sonicated for 1 hour. The eluate was evaporated in a vacuum concentrator (Speed Vac SC-200, ThermoFisher Scientific) set with 30 millibars and 27g until the residue was almost dry to prevent evaporation of the most volatile polycyclic aromatic hydrocarbons. The residue was filtered with polytetrafluoroethylene membrane (Acrodisc CR 13 mm, 0.45 μm, Pall Life Sciences) before it was analyzed with a high-performance liquid chromatography device (Ultimate 3000, ThermoFisher Scientific) equipped with a fluorescence detector (FLD-3000RS), UV detector (VWD-3000), and a separation column Nucleodur EC 150 × 3 mm C18 3 μm (Macherey-Nagel) under isocratic conditions (1.2 mL · min −1
). We injected 2 μL into the high-performance liquid chromatography chain; methanol/ water (70/30) with acetonitrile was the eluent solvent at an initial ratio of 100% to 0% (4 minutes) and a linear gradient up to 100% acetonitrile (12 minutes). We did not analyze polycyclic aromatic hydrocarbons generated by conventional cigarettes and present the mean values in the 35 best-selling cigarettes brands in the United States, as reported by Vu et al. 5 We monitored the temperature near the heater blade inside the IQOS holder and the core of the conventional cigarette at a sampling rate of 3 Hz with a type k thermocouple.
Results | Volatile organic compounds, polycyclic aromatic hydrocarbons, and carbon monoxide were present in IQOS smoke (Table) . The temperature of the IQOS was lower (330°C) than the conventional cigarette (684°C). 5 The IQOS smoke had 84% of the nicotine found in conventional cigarette smoke.
Discussion | The smoke released by IQOS contains elements from pyrolysis and thermogenic degradation that are the same harmful constituents of conventional tobacco cigarette smoke. International experts were invited by PMI to describe the IQOS aerosol; one expert claims that "less than 2% by weight of the aerosol components may derive from the pyrolysis of the tobacco substrate which would not be sufficient to characterize the aerosol as 'smoke.'" 6(p 2) In contrast, our analyses reveal that advertising slogans such as "heat-not-burn" are
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